Journal
ANNALS OF NEUROLOGY
Volume 76, Issue 6, Pages 769-783Publisher
WILEY
DOI: 10.1002/ana.24291
Keywords
-
Categories
Funding
- NIH
- NINDS [NS050425, NS058714, NS41509, NS075321]
- Michael J. Fox Foundation
- Murphy Fund
- American Parkinson Disease Association (APDA) Center for Advanced PD Research at Washington University
- Greater St Louis Chapter of the APDA
- McDonnell Center for Higher Brain Function
- Barnes-Jewish Hospital Foundation (Elliot Stein Family Fund for PD Research)
- Barnes-Jewish Hospital Foundation (Parkinson Disease Research Fund)
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [U54TR001456] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041509, R01NS050425, R01NS058714, R01NS075321, U54NS065701] Funding Source: NIH RePORTER
Ask authors/readers for more resources
In this grand rounds, we focus on development, validation, and application of neuroimaging biomarkers for Parkinson disease (PD). We cover whether such biomarkers can be used to identify presymptomatic individuals (probably yes), provide a measure of PD severity (in a limited fashion, but frequently done poorly), investigate pathophysiology of parkinsonian disorders (yes, if done carefully), play a role in differential diagnosis of parkinsonism (not well), and investigate pathology underlying cognitive impairment (yes, in conjunction with postmortem data). Along the way, we clarify several issues about definitions of biomarkers and surrogate endpoints. The goal of this lecture is to provide a basis for interpreting current literature and newly proposed clinical tools in PD. In the end, one should be able to critically distinguish fact from fantasy. Ann Neurol 2014;76:769-783
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
